BionimeTPE:4737 65 EBITDA Margin % is -13.10% as of Dec. 2025. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.96 (Fairly Valued). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Bionime ranks worse than 61.27% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bionime's EBITDA for the
three
months ended in Dec. 2025 was NT$-56 Mil. Bionime's Revenue for the
three
months ended in Dec. 2025 was NT$427 Mil. Therefore, Bionime's EBITDA margin for the quarter that ended in Dec. 2025 was -13.10%.
Bionime (TPE:4737) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bionime EBITDA Margin % Related Terms
Bionime EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bionime's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4737 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Bionime's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bionime's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a EBITDA Margin % of -13.10% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bionime and its competitors. According to the industry distribution chart, Bionime ranks #500 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 61.3%.
Is Bionime's EBITDA Margin % too high?
Bionime's current EBITDA Margin % is -13.10%. Based on the distribution chart, Bionime ranks #500 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #500 out of 816 companies for EBITDA Margin %. This places Bionime in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bionime and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionime's current EBITDA Margin % is -13.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.96, compared to a current price of NT$57.10 — trading 3.2% below its estimated fair value. The current EBITDA Margin % is -13.10%. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bionime (TPE:4737), the current EBITDA Margin % is -13.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be undervalued.
The current stock price of NT$57.10 is trading 3.2% below its estimated GF Value™ of NT$58.96.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
EBITDA Margin %: -13.10%
GF Value™: NT$58.96 vs. price of NT$57.10 (3.2% below fair value)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score
Get the complete analysis for TPE:4737
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
